Belite Bio (NASDAQ:BLTE - Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.02), Zacks reports.
Belite Bio Price Performance
NASDAQ:BLTE traded down $0.45 during trading hours on Friday, hitting $67.28. The company's stock had a trading volume of 17,485 shares, compared to its average volume of 49,744. Belite Bio has a twelve month low of $31.01 and a twelve month high of $86.53. The stock has a fifty day simple moving average of $59.24 and a 200-day simple moving average of $60.71. The company has a market capitalization of $2.14 billion, a P/E ratio of -60.61 and a beta of -1.54.
Wall Street Analyst Weigh In
BLTE has been the subject of a number of analyst reports. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Belite Bio in a research note on Tuesday. Benchmark boosted their target price on shares of Belite Bio from $57.00 to $79.00 and gave the company a "buy" rating in a research report on Tuesday, January 21st. Finally, HC Wainwright reiterated a "buy" rating and set a $100.00 price target on shares of Belite Bio in a research report on Tuesday.
Read Our Latest Report on BLTE
Belite Bio Company Profile
(
Get Free Report)
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.
See Also
Before you consider Belite Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Belite Bio wasn't on the list.
While Belite Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
